The Role of Cannabinoid Type 2 Receptors in Parkinson’s Disease
Maria Sofia Basile | Emanuela Mazzon | Maria Sofia
Moreover, the alterations in the expression of CB2 receptors observed in brain tissues from PD animal models and PD patients suggest the potential value of CB2 receptors as possible novel biomarkers for PD. The Cannabinoid Type 2 (CB2) Receptors in PD Different preclinical and clinical studies have investigated the CB2 receptors in PD, suggesting their potential as possible biomarkers for PD and as promising therapeutic targets for alleviating parkinsonian symptoms and slowing disease development in PD patients [28,29]. Since it has been shown that the anti-inflammatory and antioxidant effects of BCP in the rotenone-induced PD rat model were mediated by the activation of CB2 receptors, it should be considered that CB2 receptors could be a promising therapeutic target for PD and that BCP might represent a potential interesting molecule for PD treatment [67]. Furthermore, preclinical studies in PD animal models have shown that, in addition to the pharmacological activation of CB2 receptors, the overexpression of CB2 receptors could also exert neuroprotective effects [72]. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson’s disease.